TREATMENT OUTCOMES OF PROLONGED INDUCTION OR RE-ESCALATION DOSING OF UPADACITINIB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Annadurai, Vasantham
Axenfeld, Ellen
Faye, Adam S.
Axelrad, Jordan E.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1859
引用
收藏
页码：S1147 / S1147
页数：1
相关论文
共 50 条
  • [1] Treatment Outcomes of Prolonged Induction or Re-Escalation Dosing of Upadacitinib in Patients With Inflammatory Bowel Disease
    Axenfeld, Ellen
    Annadurai, Vasantham
    Clinton, Joseph
    Frohlinger, Michael
    George, Lauren
    Faye, Adam S.
    Cross, Raymond K.
    Axelrad, Jordan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S936 - S937
  • [2] Real World Outcomes of Upadacitinib Induction Therapy for Patient with Inflammatory Bowel Disease in Korea
    Ye, B. D.
    Kim, M. K.
    Hong, S. W.
    Hwang, S. W.
    Park, S. H.
    Yang, D. H.
    Byeon, J. S.
    Myung, S. J.
    Yang, S. K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1247 - i1249
  • [3] Induction treatment with upadacitinib is associated with high rate of clinical response in patients with refractory Inflammatory Bowel Disease
    Kitsou, V
    Ioannou, A.
    Kokkotis, G.
    Chalakatevaki, K.
    Laoudi, E.
    Leonidakis, G.
    Michopoulos, S.
    Zampeli, E.
    Bamias, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1750 - i1751
  • [4] UPADACITINIB FOR THE TREATMENT OF REFRACTORY PEDIATRIC INFLAMMATORY BOWEL DISEASE
    Nema, Noor
    Dawany, Noor
    Albenberg, Lindsey
    Baldassano, Robert N.
    Boyer, Brooke
    Constant, Brad D.
    Grossman, Andrew B.
    Mitchel, Elana
    Patel, Trusha
    Stein, Ronen E.
    Kelsen, Judith R.
    Conrad, Maire A.
    GASTROENTEROLOGY, 2023, 164 (06) : S59 - S60
  • [5] Off-label dose escalation of Ustekinumab in Inflammatory Bowel Disease patients. Incidence rate, timing, dosing patterns and outcomes
    Garcia-Morales, N.
    Carmona, A.
    Ayude, M.
    Gayoso-Rey, M.
    Agra-Blanco, I.
    Parga, M. L. De Castro
    Rodriguez-Prada, I.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1662 - I1662
  • [6] OUTCOMES OF DOSE ESCALATION WITH ADALIMUMAB (ADA) IN INFLAMMATORY BOWEL DISEASE
    Dillon, A.
    Rowan, C.
    Gibson, D.
    Keegan, D.
    Byrne, K.
    Mulcahy, H.
    Cullen, G.
    Doherty, G.
    GUT, 2013, 62
  • [7] PREDICTORS AND OUTCOMES OF VEDOLIZUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Levine, Louis
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    GASTROENTEROLOGY, 2021, 160 (06) : S703 - S703
  • [8] PREDICTORS AND OUTCOMES OF USTEKINUMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Petrov, Jessica C.
    Fine, Sean
    Al Bawardy, Badr
    GASTROENTEROLOGY, 2022, 162 (07) : S824 - S824
  • [9] Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib
    Odah, Tarek
    Karime, Christian
    Desai, Aakash
    Picco, Michael F.
    Kinnucan, Jami A.
    Hashash, Jana G.
    Farraye, Francis A.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (10) : 3911 - 3919
  • [10] Treatment of inflammatory bowel disease: 'early hit' or stepwise escalation
    Sandborn, WJ
    Gastroenterology Yesterday - Today - Tomorrow: A Review and Preview, 2005, 144 : 299 - 304
12345